1.

IN2 MODELING LONG-TERM MORTALITY AND MORBIDITY IMPACT WITH ENTECAVIR TREATMENT IN CHB PATIENTS IN BELGIUM

1.

Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups

1.

Visie voor behoud en herstel van graslanden met natuurwaarden: soortenrijke cultuurgraslanden: landbouwkundige waarden en mogelijkheden tot verweving

1.

Prevalence and risk factors of hepatitis B virus infection in Middle-Limburg Belgium, year 2017: Importance of migration.

2.

Prevalence and risk factors of hepatitis B virus infection in Middle-Limburg Belgium, year 2017: Importance of migration.

3.

Prevalence and risk factors of hepatitis B virus infection in Middle-Limburg Belgium, year 2017: Importance of migration.

1.

PGI14 Resource Use and Cost of Hepatitis C Related Care in Belgium

1.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon alpha 2b and ribavirin treatment according to the stage of liver fibrosis...

1.

HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster

2.

HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster

3.

HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster

1.

Experience with Direct Acting Agents for the Treatment of Hepatitis C in Flanders.

1.

Multicenter Belgian experience of sofosbuvir (medical need program) in very difficult-to-treat HCV patients: safety and efficacy results.

1.

Multicenter Belgian experience of sofosbuvir medical need program in pre-and post-liver transplantation patients: safety and efficacy results.